Jonathan Shillingford

  • Ph.D.
  • Scientific Knowledge Manager
  • Intervention Insights
15

Publications

--

Readers

Research Interests

Personalized medicine molecular and biological drug targets oncology

About

I have spent most of my life in the realm of scientific research thanks in large part to the enthusiasm of a few teachers I had back in school. I pursued my higher education in the UK where I obtained an undergraduate degree (B.Sc.) in cell and molecular biology and a graduate degree (Ph.D.) in biomolecular physiology. From there, I moved across the pond to the NIH (Bethesda, MD) where I was engaged in a postdoctoral position in the field of mammary gland biology with emphasis on the use of the mouse as a model system. Following my postdoc, I moved westwards to Cleveland, OH and then Santa Barbara, CA where I studied polycystic kidney disease (PKD) with emphasis on targeting aberrant molecular pathways to aid in the informed design of therapeutic drug approaches. I recently moved back east to take a senior scientist position with a personalized medicine company in Grand Rapids, MI where I am involved in leveraging, curating, documenting, and building their scientific knowledge base for use in their OncInsights report generation that helps inform physicians of potential targeted therapies for individual cancer patients.

Publications

Polycystin-1 regulates STAT activity by a dual mechanism.

Talbot J, Shillingford J, Vasanth S, Doerr N, Mukherjee S, Kinter M, Watnick T, Weimbs T

Proceedings of the National Academy of Sciences of the United States of America (2011)

  • -- Readers Readers not available. This publication is not currently accessible in the Mendeley catalog.

Signal transducer and activator of transcription-6 (STAT6) inhibition suppresses renal cyst growth in polycystic kidney disease.

Olsan E, Mukherjee S, Wulkersdorfer B, Shillingford J, Giovannone A, Todorov G, Song X, Pei Y, Weimbs T

Proceedings of the National Academy of Sciences of the United States of America (2011)

  • Get full text at journal
  • -- Readers Readers not available. This publication is not currently accessible in the Mendeley catalog.

Rapamycin Ameliorates PKD Resulting from Conditional Inactivation of Pkd1

Shillingford J, Piontek K, Germino G, Weimbs T

Journal of The American Society Of Nephrology (2010)

  • -- Readers Readers not available. This publication is not currently accessible in the Mendeley catalog.

Acute Myeloid Leukemia-Associated Mkl1 (Mrtf-a) Is a Key Regulator of Mammary Gland Function

Sun Y, Boyd K, Xu W, Ma J, Jackson C, Fu A, Shillingford J, Robinson G, Hennighausen L, Hitzler J, Ma Z, Morris S

Molecular and Cellular Biology (2006)

  • -- Readers Readers not available. This publication is not currently accessible in the Mendeley catalog.

The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease

Shillingford J, Murcia N, Larson C, Low S, Hedgepeth R, Brown N, Flask C, Novick A, Goldfarb D, Kramer-Zucker A, Walz G, Piontek K, Germino G, Weimbs T

Proceedings of the National Academy of Sciences of the United States of America (2006)

  • -- Readers Readers not available. This publication is not currently accessible in the Mendeley catalog.

Professional experience

Scientific Knowledge Manager

Intervention Insights

January 2012 - Present

Project Scientist

UC Santa Barbara

June 2005 - December 2011 (6 years 6 months)

Education history

University of Wales Aberystwyth Institute of Biological Environmental and Rural Sciences

Ph.D.

September 1993 - November 1997 (4 years 2 months)

University of Wolverhampton

B.Sc. (hons)

September 1990 - June 1993 (2 years 9 months)